As part of Genzyme's commitment to supporting optimal patient care and sustainable health care systems globally, we recognise the importance of fully understanding the needs of the patient communities we serve. We've learned that one of the best ways to accomplish this is by working with patient organisations, who are closely connected to patients' most important concerns and interests.
While partnering with these organisations has long been fundamental to Genzyme's culture and approach, in 2011 Genzyme Australia and New Zealand established our internal Patient Advocacy group to formalise our collaborations with the advocacy community. Our Patient Advocacy Director champions the patient perspective within Genzyme, and works with Multiple Sclerosis, rare diseases and thyroid cancer organisations to:
- Raise awareness and disseminate disease and health care educational information;
- Support access to therapies;
- Help foster a sense of community among patients and their families;
- Develop programs, such as training sessions and networking events, that support advocacy group leaders; and
- Partner with Australian advocacy groups to work towards an Australian National Rare Disease policy.
MPS Awareness Day 2014
Kaitie is an Australian girl who lives with MPS. It is a rare disease that affects many parts of her body. Told through the eyes of her younger brother, they share their story of courage, hope and love.
Read the full story
Genzyme provides financial support to patient organisations in the form of grants, which are administered in close compliance with all relevant regulations, to help fund the organisations' events, outreach efforts, and other activities.
To ensure that our relationships with patient organisations are thoughtful and transparent, we are guided by the following principles:
Genzyme recognises that as a global company, we are subject to often differing laws, rules, and regulations in the many locations in which we do business, and we will always comply with local rules involving interactions with patient organisations.
- We will respect and ensure the independence of patient organisations in their policies, decisions, and activities, never perceiving or placing their interests as subordinate to our own.
- Genzyme will neither request nor expect patient organisations to promote any Genzyme product or service.
- The scope and objectives of any Genzyme collaboration with a patient organisation will be open, transparent, and ethical.
- Genzyme will respect the privacy of all personal information and data we may receive from patient organisations and will not expect them to provide us with any personal patient or family information.
- We never require that a patient organisation receive funding solely from Genzyme, nor will we seek to exclude anyone, including competitors, from making contributions to these organisations. Although there may be occasions when we are the sole source of support (most likely with new organisations focused on rare diseases), we strongly encourage organisations to pursue and establish multiple funding sources.
We regularly publish information about the patient organisations we contribute funds to.
Download the list of HCOs to which Sanofi provided financial support in 2013.